Physician

Mark M Tungesvik, MD

According to 2025 Medicare claims, Mark Tungesvik, MD (NPI: 1497723472) practices hematology/oncology in the Columbia, MO market, with the plurality of this provider's patient population coming from Boone, MO. This provider's primary affiliated billing organization is MISSOURI CANCER ASSOCIATES LLC (NPI: 1215947338; TIN: 431763016) and primary practice location at 65201-7167. Tungesvik is affiliated with the Aledade 98 MO MSSP Enhanced (ACO ID: A4998) and Aledade 93 National MSSP Enhanced (ACO ID: A5206), participating under the MSSP model.

Tungesvik's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 926 traditional Medicare patients, billed 194,394 HCPCS/CPT codes, and received $3,145,923 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,919 prescription claims across 333 beneficiaries totaling $5,214,765 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 34 claims. Open Payments data shows 130 records totaling $2,280. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,448,064 to $3,145,923. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,266,136 to $5,214,765. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $13,669 to $7,351.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	688	158,000	$1,448,064
2016	790	266,098	$2,757,875
2017	805	322,762	$3,059,209
2018	1,031	231,577	$2,802,401
2019	1,024	244,451	$2,963,595
2020	1,004	263,912	$3,512,540
2021	1,100	341,442	$4,226,709
2022	1,106	398,584	$4,268,429
2023	1,216	328,665	$4,680,694
2024	926	194,394	$3,145,923

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	242	1,962	$2,266,136
2016	294	2,182	$2,326,340
2017	274	2,062	$2,772,440
2018	295	2,047	$2,745,316
2019	338	2,273	$4,399,029
2020	316	2,285	$4,722,093
2021	345	2,386	$5,432,787
2022	368	2,387	$5,614,250
2023	349	2,051	$4,334,216
2024	333	1,919	$5,214,765

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	28	147	$41,649
2016	33	192	$42,688
2017	N/R	92	$24,138
2018	40	153	$23,329
2019	43	161	$16,435
2020	34	162	$11,587
2021	N/R	93	$4,837
2022	N/R	104	$4,391
2023	N/R	34	$1,842
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	256	544	$88
96413	Administration of chemotherapy into vein, 1 hour or less	156	378	$86
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	244	335	$56
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	252	437	$12
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	152	16,100	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	65	1,806	$1,130,287
Pomalyst	Pomalidomide	33	924	$763,258
Fotivda	Tivozanib Hcl	15	420	$455,200
Jakafi	Ruxolitinib Phosphate	26	748	$313,918
Imbruvica	Ibrutinib	19	532	$298,595

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	130	$2,280	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark M. Tungesvik, MD?

Tedicare shows public-source Medicare data for Mark M. Tungesvik, MD (NPI 1497723472), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark M. Tungesvik, MD have ACO affiliation data?

Mark M. Tungesvik, MD is shown with ACO affiliation data for Aledade 98 MO MSSP Enhanced (MSSP, ACO ID A4998) and Aledade 93 National MSSP Enhanced (MSSP, ACO ID A5206).

What billing organization is linked to Mark M. Tungesvik, MD?

Mark M. Tungesvik, MD is linked to MISSOURI CANCER ASSOCIATES LLC (billing NPI 1215947338) in the available physician profile data.

Does Mark M. Tungesvik, MD have Open Payments data?

Mark M. Tungesvik, MD has 130 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.